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Abstract To investigate natural killer (NK) and lym-
phokine-activated killer (LAK) cell functions from 10
healthy dogs and 29 dogs with a variety of spontaneous
neoplasms, large granular lymphocytes (LGLs) from
blood samples were separated by a 58.5% Percoll den-
sity gradient. LGLs were stimulated with a low dose of
recombinant human interleukin 2 (rhIL-2) for 7 days.
Cytotoxicity of eﬀector cells against the susceptible
CTAC cell line was measured before and after stimula-
tion. Compared with those before stimulation, the per-
centage of LGLs after stimulation with rhIL-2 was
found to be signiﬁcantly increased (P<0.01) in both
dogs with tumors and controls. However, the increase
was signiﬁcantly higher in control animals, indicating a
defect in proliferation ability of NK cells in canine tu-
mor patients. After stimulation with rhIL-2, lympho-
kine-activated killer (LAK) cell activity in dogs with
tumors was signiﬁcantly lower (P<0.01) when com-
pared with controls. Reduced cytotoxicity of rhIL-2–
activated NK cells in dogs with tumors seems to be
attributable to the presence of a diminished proliferative
capacity of NK cells and a decreased ability of LAK
cells to lyse target cells. Further knowledge of the precise
function of IL-2–activated NK cells in dogs with tumors
may help to optimize new and therapeutically beneﬁcial
treatment strategies in canine and human cancer
patients. Our ﬁndings suggest that the dog could also
serve as a relevant large animal model for cancer im-
munotherapy with IL-2.
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Introduction
Interleukin 2 (IL-2) plays a central role in the regulation
of cell-mediated immunity through stimulation and
proliferation of T cells, natural killer (NK) cells, and
activated B cells. Human and murine lymphocytes can
be activated by IL-2 to become cytotoxic, with a wide-
ranging lymphokine-activated killer (LAK) cell activity,
able to lyse both freshly NK cell-resistant isolated
autologous and cultured allogenic tumor cells [8, 9]. It
has been shown that most LAK cell activity mediated by
blood lymphocytes is attributable to stimulation of NK
cells by IL-2 [11]. Both NK and LAK cell activity appear
to have an active role in resistance to cancer develop-
ment and spread.
The systemic administration of LAK cells and/or
recombinant human IL-2 (rhIL-2) has shown biologic
and therapeutic eﬃcacy in the treatment of human pa-
tients with advanced neoplasms [22]. However, further
studies are still necessary to determine the optimal dos-
ages and combinations of chemotherapeutic agents,
timing of surgery, the use of immune biologic response
modiﬁers such as IL-2, and to understand the mecha-
nisms used by some tumors to escape from immune at-
tack [3, 17, 23].
Due to a high prevalence of spontaneous neoplasms,
dogs are the most frequent tumor patients in veterinary
practice, but little is known about the cellular immune
response against neoplastic cells in this species. It has
been shown recently that NK cell activity is depressed in
dogs with certain types of tumors [6, 20]. IL-2 is able to
activate in vitro cytotoxic function in peripheral blood
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lymphocytes from healthy dogs [10, 12, 15, 21]. How-
ever, information about LAK cell activity in canine tu-
mor patients is limited. After stimulation with rhIL-2,
LAK cell activity was not found to be signiﬁcantly in-
creased in ﬁve dogs with lung tumors when compared to
values before stimulation [15]. LAK cells from dogs
implanted with transmissible venereal sarcoma showed
serial growth in rhIL-2–containing culture medium for
at least 2 weeks without losing in vitro antitumor
activity [16].
In the dog, histologic behavior of tumors, patterns of
tumor progression, metastasis, and clinical signs of these
spontaneous neoplasms are often identical to those in
human patients. Because of this, numerous therapeutic
approaches used for treatment of human cancer have
been adapted to canine patients. The use of rhIL-2 and/
or LAK cells alone or in combination with other ther-
apies might be an additional helpful tool in the treat-
ment of canine neoplasms. The dog may also serve as an
additional large animal model to improve cancer (im-
muno-) therapy in man.
Most of the publications to date are based on NK
and LAK cell activity measurements performed with the
51Cr-release assay (CRA). In the present study, the
colorimetric rose bengal assay (RBA) was used to
measure cytotoxicity [7]. It has been previously shown
that the RBA measures both apoptotic and necrotic cells
and therefore provides a more sensitive tool to assess
cytotoxicity in dogs [24].
The purpose of this study was to assess the inﬂuence
of tumor disease on IL-2–activated NK cells and to
better support the future use of low-dose rhIL-2 as an
immunotherapeutic agent in dogs. To our knowledge,
this is the ﬁrst study in which LAK cell activity was
examined in dogs with a variety of diﬀerent tumors.
Material and methods
Animals
A total of 29 dogs with diﬀerent benign and malignant
spontaneous neoplasms at diﬀerent stages were exam-
ined (3 benign and 26 malignant neoplasms; Table 1).
The average age was 7 years. Only previously untreated
dogs were considered for this study. The control group
included ten healthy adult beagle dogs, age-matched
with the patient population and vaccinated against lep-
tospirosis, distemper, parvovirosis, rabies, and infectious
canine hepatitis. Blood sampling was not done before
3 months after vaccination. Diagnoses of tumors were
conﬁrmed by histologic examination according to the
WHO International Histological Classiﬁcation of
Tumors of Domestic Animals.
Preparation of large granular lymphocytes (LGL)
Lymphocytes were isolated from heparinized blood
samples by a 58.5% Percoll (Amersham Biosciences,
Sweden) density gradient (v/v, speciﬁc gravity 1.073), as
previously described [7]. Heparinized venous blood was
mixed with two parts RPMI 1640 (PAA, Austria) cul-
ture medium containing 10,000 U/ml penicillin and
10,000 ll/ml streptomycin (Biochrom KG, Germany)
and layered over Percoll. Following centrifugation at
400 g for 25 min, whole blood mononuclear cells were
removed from the gradient interface and washed in
RPMI 1640. Separated cells were resuspended in RPMI
1640 supplemented with 10% fetal calf serum and cul-
tured in plastic culture dishes at 37C in a humidiﬁed
5% CO2 atmosphere for 1 h to remove adherent cells.
Stimulation of LGL with rhIL-2
Nonadherent eﬀector cells at a concentration of 5.0·106
cells/ml were stimulated twice (day 0 and 3) with
100 IU/ml rhIL-2 and cultured for 7 days. At day 3, old
culture medium was removed and fresh culture medium
with 100 IU/ml rhIL-2 was added. Cultures were placed
into 25-cm2 tissue culture ﬂasks and incubated at 37C
in a humidiﬁed 5% CO2 atmosphere.
Morphologic evaluation of LGL
Freshly isolated and rhIL-2-activated lymphocytes were
stained with trypan blue to assess viability, counted in a
hemocytometer, and diluted to appropriate concentra-
tions for further assays. Additionally, 2.0·105 cells were
centrifuged onto microscope slides using a cytospin
Table 1 Diﬀerent tumor groups
aIncluding one benign tumor
Tumor type n Median age
(year)
Mean age
(year)
Minimum
(year)
Maximum
(year)
Mammary adenomas 2 10.0 10.0 10.0 10.0
Mammary carcinomas 2 7.0 7.0 6.0 8.0
Other carcinomas 3 8.0 7.5 2.0 12.0
Malignant mixed mammary
tumors
3 9.0 9.5 8.0 11.0
Lymphomas 7 6.5 6.5 5.0 8.0
Myeloid neoplasms 4 4.5 4.0 1.0 6.0
Other sarcomas 5 12.0 10.0 5.0 13.0
Other tumorsa 3 5.0 4.5 2.0 7.0
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centrifuge (Shandon Elliot Cytospin, Germany). Cells
were stained with May-Gruenwald-Giemsa according to
a standard manual procedure. Both freshly isolated and
rhIL-2–activated NK cells were identiﬁed morphologi-
cally as LGLs with a large, eccentric, often indented
nucleus and azurophilic granules in the cytoplasm [4].
Cytotoxicity of freshly isolated NK cells
and rhIL-2–activated NK cells
The canine thyroid adenocarcinoma cell line (CTAC)
was used as the target cell line [13]. Vero cells were used
as the negative control. Cytotoxicity of eﬀector cells was
measured before and after the stimulation with rhIL-2.
For determination of NK cell activity (natural cytotox-
icity), only nonadherent blood mononuclear cells were
used as eﬀector cells.
For the measurement of cytotoxicity, the colorimetric
RBA was used [7]. Both freshly isolated NK cells and
rhIL-2–activated NK cells were coincubated with CTAC
and Vero cells in rigid 96-well ﬂat-bottomed plates at
eﬀector-to-target cell ratios of 50:1 and 25:1. CTAC or
Vero cells without eﬀector cells served as controls.
Triplicate cultures were incubated at 37C in a humidi-
ﬁed 5% CO2 atmosphere. After 14 h incubation, lysed
target cells and eﬀector cells were removed. The
remaining adherent target cells were exposed to the rose
bengal dye for 3 min. After three washes, rose bengal
dye was released into the supernatant with ethanol, and
the optical density (OD) was measured using an ELISA
reader.
Cytotoxicity was calculated from the mean of each set
of triplicates using the formula:
Cytotoxicity in% ¼ 100 OD test
OD control
 100
 
Statistical analysis
Data from the separation of LGLs and cytotoxicity
against CTAC cells were analyzed by the two-factorial
variance analysis with repeated measures. Medians, and
ﬁrst and third quartiles were calculated and are shown in
the ﬁgures. SPSS version 10 for Windows was used for
statistical analysis. Values with P<0.01 were considered
to be statistically signiﬁcant.
Results
Preparation of LGLs
After stimulation with rhIL-2, the percentage of LGLs
in cell preparations was signiﬁcantly increased (P<0.01)
in both dogs with tumors and healthy controls. How-
ever, the increase of LGLs in dogs with tumors was
signiﬁcantly lower (P<0.01) than in healthy controls
(Fig. 1).
Before stimulation with rhIL-2, the median percent-
age of LGLs in cell preparations from dogs with tumors
was 2.5% (mean 2.7%; range 1.0–5.7%), which was
comparable to healthy controls (median 2.9%; mean
2.8%; range 1.0–4.0%). After stimulation with rhIL-2,
the median percentage of LGLs was only 5.5% (mean
6.7%; range 1.0–16.5%) in dogs with tumors, while it
was 11.0% in healthy controls (mean 17.6%; range 6.5–
48.5%). Cells stimulated with rhIL-2 were mainly com-
posed of small- to middle-sized lymphocytes and typical
LGLs (Fig. 2).
Cytotoxicity of freshly isolated NK cells
and rhIL-2–activated NK cells
In Figs. 3 and 4, cytotoxicity of freshly isolated NK cells
and rhIL-2–activated NK cells at eﬀector-to-target cell
ratios of 50:1 and 25:1 in dogs with tumors and healthy
controls are shown.
After stimulation with rhIL-2, the overall cytotoxicity
at both eﬀector-to-target cell ratios was found to be
signiﬁcantly increased (P<0.01) in dogs with tumors
and healthy controls. However, the increase in cyto-
toxicity in dogs with tumors was signiﬁcantly lower
(P<0.01) than in controls.
In dogs with tumors, median cytotoxicity before
stimulation at an eﬀector-to-target cell ratio of 50:1 was
12.1% (mean 15.1%; range 1.9–31.0%), while it was
Fig. 1 Percentage of isolated LGLs before and after stimulation
with rhIL-2; two-factorial variance analysis with repeated mea-
sures; median, and ﬁrst (Q1) and third (Q3) quartile, minimum and
maximum; mean eﬀect group (tumor vs healthy control), mean
eﬀect time (before vs after stimulation) and interaction group · -
time: P<0.01
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only 16.6% after stimulation (mean 27.7%; range 3.0–
93.6%). In contrast, median cytotoxicity in healthy
controls dramatically increased from 9.8% (mean 8.6%;
range 1.5–13.4%) before stimulation, to 73.8% (mean
74.9%; range 55.7–89.9%) after stimulation (Fig. 3).
At an eﬀector-to-target cell ratio of 25:1, cytotoxicity
in dogs with tumors after stimulation (median 13.1%;
mean 26.5%; range 2.6–92.5%) was comparable to
cytotoxicity before stimulation (median 17.1%; mean
17.3%; range 0.3–75.5%). However, median cytotoxicity
in healthy controls increased from 11.8% (mean 11.8%;
range 3.4–22.2%) before stimulation, to 54.8% (mean
56.5%; range 20.8–94.2%) after stimulation (Fig. 4).
No cytotoxicity against Vero cells (negative control)
in either dogs with tumors or healthy controls was ob-
served before and after the stimulation with rhIL-2 (data
not shown).
Discussion
Natural killer and LAK cells, through the use of im-
mune biologic modiﬁers, have been demonstrated to
have a therapeutic role in the treatment of human can-
cers. Complete regression was seen in human patients
after adoptive immunotherapy [22].
So far, only little is known about LAK cell activity in
dogs with tumors. Previous studies have shown impaired
cellular immune functions such as NK cell activity or
mitogen-induced lymphocyte proliferation in dogs with
diﬀerent tumors [5, 6, 20, 25]. These ﬁndings supported
the hypothesis that cellular immune defects are also
present in canine tumor patients.
In the present study, rhIL-2 was able to increase the
number of LGLs from both dogs with tumors and
controls, after stimulation for 7 days. This demonstrates
that rhIL-2 is also able to stimulate proliferation of NK
cells in dogs with tumors. However, the increase of
LGLs after stimulation with rhIL-2 was signiﬁcantly
lower in dogs with tumors. The results of this study
suggest that reduced cytotoxicity of rhIL-2–activated
NK cells in dogs with tumors is partly attributable to the
presence of a diminished proliferative capacity of NK
cells. In addition, the cytotoxic response of rhIL-2–
activated NK cells from canine tumor patients seems
to be depressed since the increase of LGLs after
Fig. 2 Lymphokine-activated killer (LAK) cells with the typical
morphology of LGLs
Fig. 3 Cytotoxicity before and after stimulation with rhIL-2 at an
eﬀector-to-target cell ratio of 50:1; two-factorial variance analysis
with repeated measures; median, Q1, Q3, minimum and maximum;
mean eﬀect group (tumor vs healthy control), mean eﬀect time
(before vs after stimulation), and interaction group · time: P<0.01
Fig. 4 Cytotoxicity before and after stimulation with rhIL-2 at an
eﬀector-to-target cell ratio of 25:1; two-factorial variance analysis
with repeated measures; median, Q1, Q3, minimum and maximum;
mean eﬀect group (tumor vs healthy control), mean eﬀect time
(before vs after stimulation), and interaction group · time: P<0.01
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stimulation with rhIL-2 did not lead to increased cyto-
toxicity of these cells.
These observations support the hypothesis that there
is also a defect in LAK cell activity in dogs with tumors,
as previously described in dogs with lung tumors [15].
Reduced LAK cell activity was also observed in human
patients with bronchial carcinoma, advanced gastroin-
testinal cancer, breast carcinoma, and melanoma [1, 2,
14, 18]. In patients with melanoma, the decrease in LAK
cell activity was also correlated with increasing stage of
the tumor disease [1].
Complete tumor regression in dogs with melanoma
was observed after treatment with tumor necrosis factor
(TNF) and IL-2 [19], whereas in other tumor types such
as squamous cell or mammary carcinoma, there was no
regression at all. Modiﬁed response to TNF and IL-2 in
combination with an impaired activity of NK cells in
dogs with certain tumor types may explain the failure of
immunotherapy in some canine tumor patients. In the
present study, there was a considerable variance of val-
ues in dogs with tumors, which also supports the
hypothesis that there might be diﬀerences between dif-
ferent histologic types of tumors. In a previous study,
decreased NK cell activity was seen in dogs with ad-
vanced tumor disease [6]. It remains unknown whether
there is also a modiﬁed response to IL-2 with increasing
tumor load. This needs to be veriﬁed in a follow-up
study. Further studies are also needed to clarify whether
there is also a serum suppressor factor or an elevated
prostaglandin E2 production by monocytes present in
dogs with tumors, as has been described in human
patients [1, 2].
As NK cell–restricted speciﬁc markers have not yet
been described for dogs, LGLs were identiﬁed according
to their morphology when stained manually with May-
Gruenwald-Giemsa. Cytotoxicity against Vero cells did
not increase after stimulation in both dogs with tumors
and controls. These target cells appear to be very resis-
tant to the activity of rhIL-2–activated NK cells from
the dogs. Although the CTAC cell line is considered to
be susceptible for both canine NK and LAK cells [4, 6,
7, 10, 12, 24], the authors cannot show that the results
from this cell line are representative for other established
cell lines.
In this study, the treatment of canine NK cells with a
low dose of rhIL-2 signiﬁcantly increased the percentage
of LGLs in cell preparations and the cytotoxicity of
these cells in both dogs with tumors and controls.
Therefore, the dog could serve as a relevant large animal
model for cancer immunotherapy with IL-2. Further
knowledge of the precise function of IL-2–activated NK
cells in dogs with tumors may help to optimize new and
therapeutically beneﬁcial treatment strategies in canine
and human cancer patients.
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